1887

Abstract

Voriconazole (VRC) has not previously been reported to cause angio-oedema. Here, we report a case of angio-oedema associated with VRC therapy. A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous VRC and developed angio-oedema 10 days after starting therapy. This condition rapidly diminished after administration of intravenous antihistaminics and did not necessitate cessation of VRC treatment. The treatment was continued for 6 months without recurrence of the symptoms. After 18 months, the patient was in good health. To our knowledge, this is the first report of an angio-oedema associated with VRC.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47299-0
2008-08-01
2019-10-15
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/8/1028.html?itemId=/content/journal/jmm/10.1099/jmm.0.47299-0&mimeType=html&fmt=ahah

References

  1. Ally, R., Schurmann, D., Kreisel, W., Carois, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P. & Romero, A. J. the Esophageal Candidiasis Study Group ( 2001; ). A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33, 1447–1454.[CrossRef]
    [Google Scholar]
  2. Bates, D. W., Su, L., Yu, D. T., Chertow, G. M., Seger, D. L., Gomes, D. R., Dasbach, E. J. & Platt, R. ( 2001; ). Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32, 686–693.[CrossRef]
    [Google Scholar]
  3. Denning, D. W. ( 1998; ). Invasive aspergillosis. Clin Infect Dis 26, 781–803.[CrossRef]
    [Google Scholar]
  4. Denning, D. W. & Griffiths, C. E. ( 2001; ). Mucocutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 26, 648–653.[CrossRef]
    [Google Scholar]
  5. Denning, D. W. & Stevens, D. A. ( 1990; ). Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 12, 1147–1201.[CrossRef]
    [Google Scholar]
  6. Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M. & Lode, H. ( 2002; ). Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34, 563–571.[CrossRef]
    [Google Scholar]
  7. Ghannoum, M. A. & Kuhn, D. M. ( 2002; ). Voriconazole – better chances for patients with invasive mycoses. Eur J Med Res 7, 242–256.
    [Google Scholar]
  8. Gunsilius, E., Lass-Florl, C., Mur, E., Gabl, C., Gastl, G. & Petzer, A. L. ( 1999; ). Aspergillus osteoarthritis in acute lymphoblastic leukemia. Ann Hematol 78, 529–530.[CrossRef]
    [Google Scholar]
  9. Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J. W., Kern, W. V., Marr, K. A., Ribaud, P. & other authors ( 2002; ). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347, 408–415.[CrossRef]
    [Google Scholar]
  10. Johnson, L. B. & Kauffman, C. A. ( 2003; ). Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36, 630–637.[CrossRef]
    [Google Scholar]
  11. Kirkpatrick, W. R., McAtee, R. K., Fothergill, A. W., Rinaldi, M. G. & Patterson, T. E. ( 2000; ). Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 44, 2865–2868.[CrossRef]
    [Google Scholar]
  12. Kohli, R. & Hadley, S. ( 2005; ). Fungal arthritis and osteomyelitis. Infect Dis Clin North Am 19, 831–851.[CrossRef]
    [Google Scholar]
  13. Lazarus, H. M., Blumer, J. L., Yanovicjh, S., Schlamm, H. & Romero, A. ( 2002; ). Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 42, 395–402.[CrossRef]
    [Google Scholar]
  14. Mouas, H., Lutsar, I., Dupont, B., Fain, O., Herbrecht, R., Lescure, F. X. & Lortholary, O. the Bone Invasive Aspergillosis Study Group ( 2005; ). Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 40, 1141–1147.[CrossRef]
    [Google Scholar]
  15. Murphy, M., Bernard, E. M., Ishimaru, T. & Armstrong, D. ( 1997; ). Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 41, 696–698.
    [Google Scholar]
  16. Perez-Gomez, A., Prieto, A., Torresano, M., Díez, E., Mulero, J., Labiano, I. & Andreu, J. L. ( 1998; ). Role of the new azoles in the treatment of fungal osteoarticular infections. Semin Arthritis Rheum 27, 226–244.[CrossRef]
    [Google Scholar]
  17. Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., DuPont, B., de la Torre-Cisneros, J., Just-Nübling, G., Schlamm, H. T., Lutsar, I. & other authors ( 2003; ). Voriconazole treatment for less common, emerging, or refractory fungal infections. Clin Infect Dis 36, 1122–1131.[CrossRef]
    [Google Scholar]
  18. Pfaller, M. A., Messer, S. A., Hollis, R. J. & Jones, R. N. ( 2002; ). Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillence Program, 2000. Antimicrob Agents Chemother 46, 1032–1037.[CrossRef]
    [Google Scholar]
  19. Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M. J. & Kleinermans, D. ( 2002; ). Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46, 2546–2553.[CrossRef]
    [Google Scholar]
  20. Stevens, D. A., Kan, V. L., Judson, M. A., Morrison, V. A., Dummer, S., Denning, D. W., Bennett, J. E., Walsh, T. J., Patterson, T. F. & Pankey, G. A. ( 2000; ). Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 30, 696–709.[CrossRef]
    [Google Scholar]
  21. Stratov, I., Korman, T. M. & Johnson, P. D. ( 2003; ). Management of Aspergillus osteomyelitis: report of failure of liposomal amphotericin B and response to voriconazole in an immunocompetent host and literature review. Eur J Clin Microbiol Infect Dis 22, 277–283.
    [Google Scholar]
  22. Walsh, T. J., Lutsar, I., Driscoll, T., Dupont, B., Roden, M., Ghahramani, P., Hodges, M., Groll, A. H. & Perfect, J. R. ( 2002a; ). Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21, 240–248.[CrossRef]
    [Google Scholar]
  23. Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R. & other authors ( 2002b; ). Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346, 225–234.[CrossRef]
    [Google Scholar]
  24. Wingard, J. R., Kubilis, P., Lee, L., Yee, G., White, M., Walshe, L., Bowden, R., Anaissie, E., Hiemenz, J. & Lister, J. ( 1999; ). Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29, 1402–1407.[CrossRef]
    [Google Scholar]
  25. Winkelstein, J. A., Marino, M. C., Johnson, R. B., Jr, Boyle, J., Curnutte, J., Gallin, J. I., Malech, H. L., Holland, S. M., Ochs, H. & other authors ( 2000; ). Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 79, 155–169.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.47299-0
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error